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Abstract
Background: Phenol is widely used for years as local adjuvant treatment for bone tumours. Despite its use for a
long time, no information is available about the local concentration of phenol that is achieved in an individual
patient, and the most sufficient and safe procedure to wash out the phenol after using it as local adjuvant.
Questions/purposes: 1. What is the initial local concentration of phenol in the tissue of the cavity wall after the
application of phenol? 2. How quickly is phenol 85% diluted by washing the bone cavity with ethanol 96%
solution? 3. Is the degree and speed of dilution influenced by the size of the cavity? 4. How many times should
the cavity be rinsed to obtain sufficient elimination of phenol?
Methods: A basic science study was performed at respectively 16 and 10 patients, treated by intralesional
curettage and adjuvant therapy for low-grade central chondrosarcoma of bone. Test 1:in 16 patients ten samples
were collected of the mixture of phenol and ethanol from the bone cavity. Test 2:in ten patients, two biopsy
samples were taken from the cavity wall in the bone during surgery.
Results: Phenol concentrations had wide variety in different patients, but all decreased by rinsing with ethanol.
Conclusions: Ethanol 96% is effective to wash out local applicated phenol, by rinsing the bone cavity six times.
The local concentration of phenol diminishes to an acceptable concentration of 0.2%. This study provides new
insights to safely further improve the surgical technique of intralesional treatment of bone tumours.
Background
In the surgical treatment of benign bone tumours, intra-
lesional curettage has been performed throughout the
past century. Over the recent years, its use has been
extended to low-grade intramedullary malignant tumours
in some instances. Unfortunately, this surgical technique
has the risk of local recurrence from tumour cells that
may be left behind. For this reason curettage was supple-
mented by the use of a local adjuvant, such as phenol,
liquid nitrogen or bone cement (poly methyl methacry-
late, PMMA). Various studies have demonstrated that by
using adjuvant, the results of local therapy have been
greatly improved [1-4].
With regard to liquefied phenol, only a few documen-
ted studies have been published, despite of its routine
use over a long period in orthopaedic practice. Pre-
viously, we were able to show that in case of low-grade
chondrosarcoma, phenol is able to kill tumour cells in-vi-
tro already at a concentration of 3% [5]. In clinical set-
tings, liquefied phenol is known to reduce local
recurrence rates in different benign bone tumours such
as aneurysmal bone cysts, chondroblastoma and giant
cell tumours from 41% to 7-9% [1,2]. Liquefied phenol,
containing 82.0 to 86.5% w/w phenol in water, is a col-
ourless or faintly coloured liquid. It may be used as a pre-
servative in pharmaceuticals and chemicals, but is also
widely used in household products. Liquefied phenol is
readily absorbed via inhalation, ingestion and dermal
contact, causing both local and systemic toxicity. The
elimination half-life ranges from 1-14 hours [6]. It is
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conjugates. Liquefied phenol causes cell-wall disruption,
precipitation, denaturation of proteins and coagulation
necrosis. Aqueous solutions as dilute as 10% may be
corrosive.
Clinical symptoms of phenol after ingestion may
include local corrosion with pain, nausea, vomiting and
diarrhea [6]. Systemic toxicity may consist of CNS
depression, circulatory and respiratory failure, pulmonary
edema and hepatic and renal injury. Poisoning may occur
from skin contact, especially from wounds. Applied to
the skin, phenol causes blanching and corrosion in a con-
centration of 1-2%, depending on the exposure time.
In case of surgery, a bone-window is created in order to
perform a subsequent curettage of the tumour. To ensure
that the cavity that has been formed is microscopically
tumour-free, the walls are cauterised with an 85% solution
of liquefied phenol. Given that liquefied phenol has toxic
and potentially carcinogenic properties when used sys-
temically over a longer period, the cavity is then rinsed a
number of times with a 96% solution of ethanol. The cav-
ity is filled with allograft bone-chips and the bone-window,
which has also been rinsed with liquefied phenol and etha-
nol, is placed back in position. The above mentioned sur-
gical technique has our preference given its advantage to
induce minimal local damage and a biological reconstruc-
tion. Alternative products to fill the resultant defect after
curettage are PMMA, auto graft bone chips or synthetic
bone materials.
Regarding the surgical technique, some questions
remain:
1. What is the initial local concentration of phenol in
the tissue of the cavity wall after the application of
liquefied phenol 85%?
2. How quickly is the liquefied phenol 85% diluted by
washing the bone cavity with ethanol 96% solution?
3. Is the degree and speed of dilution influenced by
the size of the cavity?
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obtain sufficient elimination of phenol?
Answering these questions will further elucidate the
safe practice of phenol-assisted, intralesional curettage
of low grade malignant intramedullary bone tumours.
Patients and methods
Patients
16 patients (5 male, 11 female) with a median age of 48
(range 26-70) at time of surgery, were treated for grade I
chondrosarcoma. The tumours are predominantly
located in the proximal humerus (7/16, 44%) and the dis-
tal femur (5/16, 31%) (Table 1). The lesions were histolo-
gically classified by an experienced pathologist according
to the recently published consensus criteria [7] and
graded according to the Evans’ grading [8].
Clinical setting
Following a trial on three patients to test the feasibility of
the study, 16 patients, suspected with grade I chondrosar-
coma following X-ray and dynamic Gd-MRI [9], were
treated according to the surgical technique described
above. Two tests were performed. Test 1 was done on all
16 patients, test 2 on 10 patients. Before performing sur-
gery including these tests, all patients were informed and
gave their approval. Patient material was used in a coded
fashion according to the local ethical regulation and in
accordance to the national ethical guidelines (Dutch orga-
nisation of scientific societies FEDERA; “Code for proper
secondary use of human tissue” in the Netherlands).
Treatment protocol
Test 1
Depending on the size of the cavity, 2 to 4 ml of liquefied
phenol 85% was applied with one or more small gauzes
at the inner surface of the wall for 3 minutes after curet-
tage of the bone tumour. Then the cavity was filled with
an ethanol 96% solution. The volume of ethanol differed
depending on the size of the cavity. Subsequently, this
mixture of phenol and ethanol was extracted by syringe
and sealed immediately in a polypropylene container.
This procedure was repeated ten times and labelled
accordingly (sample numbers I to X).
Test 2
During surgery two biopsies were taken. The first biopsy
(A)was taken after the cavity had been swabbed with the
85% phenol solution. A second biopsy (B) was taken
after the cavity had been rinsed thoroughly ten times
with ethanol, as described above (Table 2).
These biopsies (A and B), plus the ten flush solutions
(I to X) were then further investigated to determine the
concentration of phenol.
The surface area of the cavity
It is necessary to approximate the shape of the cavity,
because the actual surface area does not fit in any stan-
dard mathematical model and therefore cannot be mea-
sured with absolute precision. Therefore we projected a
cylinder over the lesion using the largest diameter of the
cartilaginous tumour of the long bones, measured in
three dimensions on the pre-operative MRI. A standard
formula was used to calculate the inner surface of this
cylindrical curetted bone cavity: 2 πr( r+h ) .Rrepre-
sents the average of half the width (mediolateral) and
half the depth (anteroposterior), which often corre-
sponds with the inside diameter of the bone. H is the
length of the tumour taken in a craniocaudal direction.
Sampling
The flush solutions, from test 1, and the bone biopsies,
from test 2, were stored in a refrigerator until analysis.
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(see phenol analysis). Bone biopsies were dispersed in
5.0 ml ethanol 96% v/v; an aliquot of this solution was
analyzed.
Phenol analysis
The phenol concentration of the ethanolic flush solu-
tions was determined by High Performance Liquid
Chromatography (HPLC) with spectrophotometric
detection. Briefly, chromatographic analysis of the sam-
ples (diluted with ethanol to fit within the concentration
range of the calibration curve, if necessary) was per-
formed on a silica reversed phase column (Nucleosil
C18, 100 × 3 mm, 5 μm particle size) with a mobile
phase consisting of 25 mM phosphate buffer containing
0,5% triethylamine pH 3.0 and acetonitrile (83 + 17, v/
v). The column flow rate was 0.4 ml/min and detection
was performed at 212 nm. The injection volume was 10
μl. The phenol concentrations in the flush solutions
were calculated from calibration graphs obtained by
simultaneous analysis of phenol standard solutions in
ethanol 96% v/v in the concentration range 30 - 1500
ppm phenol. Up to 500 ppm there was a linear relation
between response and concentration; above 500 ppm a
quadratic function had to be used. Inter-day reproduci-
bility showed a coefficient of variation of 5.1% at a con-
centration level of 50 ppm and 10.6% at 5 ppm (n = 6).
The lower limit of quantitation (LLOQ) was 5 ppm.
Basic descriptive statistics were employed.
Results
Test 1
The phenol concentrations measured in the flush solu-
tions ranged from 29 to 20974 ppm. Large inter-patient
differences were observed. Figure 1 shows a graphical
presentation of the decay in phenol concentration over
Table 1 Patient information, tumour volume and cavity surface
Patient Age/Gender PA Location Tumour volume (cm3) Cavity surface (cm2)
1 41/M CHS I Proximal humerus 27 73,4
2 39/M CHS I Distal femur 48,1 74,2
3 40/F CHS I Distal tibia 9,2 24,6
4 411 M CHS I Proximal humerus 26,3 62,3
5 45/F CHS I Proximal humerus 40,8 72,6
6 70ff CHS I Distal femur 10,9 62,3
7 55/M CHS I Distal femur 39,4 74,6
8 59/F CHS I Proximalhumerus 14,7 33,4
9 49/F CHS II Proximal humerus 9,7 25,8
10 48/F CHS I Distal femur 33 58,8
11 67/F CHS I Distal tibia 5,2 16,8
12 44/F CHS I Proximal humerus 25,8 49,4
13 33/NI CHS I Metacarpal V 4,4 15,3
14 50/F CHS I Humerus 44 74,5
15 55/F CHS I Proximal humerus 32 59,3
16 26/F CHS I Distal femur 20 51,5
Characteristics of the 16 patients where the tests during surgery were performed. Depending on the location of the chondrosarcoma, the cavity surface varies.
Table 2 Concentrations of phenol in sixteen patients during washing out phenol with ethanol
12 3 4 5 6 78 91 0 1 1 1 21 31 4 1 5 1 6
I 929 2435 8032 3264 9661 13000 289 1300 1500 1500 1500 2299 20974 1239 373 160
II 449 900 2889 730 1780 563 193 787 734 1500 1478 816 13932 889 247 118
III 177 469 2169 293 1097 201 555 473 329 539 1199 523 4652 644 159 97
IV 92 313 1019 83 944 119 156 418 249 195 495 292 1739 465 82 66
V 84 185 797 106 632 162 167 313 150 160 185 261 1932 407 77 89
VI 69 189 522 73 312 126 146 289 127 87 249 223 1287 307 82 54
VII 65 128 400 49 168 101 98 191 97 126 157 160 805 214 65 64
VIII 65 146 381 72 227 72 114 126 97 116 217 140 900 215 65 39
IX 42 325 294 59 392 138 52 124 110 57 178 111 597 162 87 42
X 105 217 279 47 200 54 64 98 88 60 143 117 417 182 60 29
Results of 16 patients (1-16); after using phenol 85% as adjuvant therapy, ethanol 96% was used to wash out the phenol; sample I to X show ppm of phenol in
ethanol; Note that the bold results are not reliable or higher measured level than in reality.
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tage of the concentration measured in the first flush
sample.
After washing the bone cavity five times with ethanol
96%, in most of the patients the phenol levels measured
are < 280 ppm.
Patient number 7 has one very high concentration of
phenol in sample III (Table 2). We can only explain this
as a sample error, because from sample IV to X the
concentration decreases.
Test 2
In Table 3 the phenol concentrations found in the biop-
sies, dispersed in 5 ml. ethanol, are presented. For all
patients the phenol concentration before (A) and after
flushing the cavity with ethanol 96% (B) is shown.
Remarkable differences were measured, quantative as
well as in reducing the concentration of phenol washed
out by ethanol.
Tumour volume
Median volume of the cavity is 24.4 cm3 (range 4-48),
and depends on the location of the tumour. The
smallest volumes are measured in the distal tibia and
fifth metacarpal bone.
No correlation is seen between the concentrations of
phenol in ethanol in large or small cavities (Figure 2).
Discussion
The use of chemical cauterization for benign and low-
grade malign bone tumours was first proposed by Blood-
good [10]. Although phenol is used for many years as
adjuvant therapy in the intralesional treatment of benign
and low-grade malignant bone tumours, no information
is available about the local concentration of phenol in
Figure 1 Concentrations of phenol in ethanol. Results of ten samples of ethanol with phenol in 16 patients; samples II to X are reproduced
as the fraction of the phenol concentration, measured in the first sample.
Table 3 Concentrations of phenol solved in 5 ml. of
ethanol during surgery
8 9 10 11 12 13 14 15 16
biopsy A (ppm) 1598 888 168 479 1043 25 572 94 144
biopsy B (ppm) 408 418 39 106 636 17 587 11 18
Results of phenol samples 9 patients (8-16); first bone biopsy (A) was taken
after application phenol 85%. After washing ten times with ethanol 85% the
second biopsy (B) was performed. The concentrations of phenol (ppm) in this
table are solved in 5 ml. of ethanol.
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wash out the phenol after the local use.
Some surgeons have a dislike to the use of phenol as
adjuvant, due to the possible predisposition to infection,
the inhibition of the incorporation of grafts, systemic
toxic effects on patients, and possible adverse effects on
personnel in the operating theatre.
In our opinion, the highest estimated risk for using
phenol is the people who work with it in the operating
room. To prevent skin contact, using the routine mea-
sures such as by wearing proper protection to hands and
face is sufficient. In case of skin contact, the skin should
be irrigated with polyethylene glycol (PEG) 400 solution,
isopropanol 70% or, if not available, with water [10-14].
During surgery, there is a risk of fire, with the evapora-
tion of ethanol and simultaneous use of electric cauteri-
zation devices, as this can cause a spark. Therefore, we
strongly recommend disconnecting the electric devices
from the moment phenol and ethanol bottles are to be
opened.
The two biopsies A and B were taken from the cavity
wall before starting washing out and after rinsing 10
times with ethanol 96%. In biopsy B, the quantity of
phenol is diminished, as expected, but still there is quite
a concentration left. This is due to the fact, that phenol
is very lipophylic and therefore not easy to remove with
ethanol 96%. The results also show remarkable differ-
ences in a quantative way. In these patients, tumour
volume, differences in dilution by wound fluid and
blood in the cavity, and differences in the ml of phenol
applicated explain these results. In patient 14, the con-
centration even increases a little bit after washing
out with ethanol. In this patient, it seems that it is
hard to wash out the local phenol from the cavity
wall.
Concerning the initial local concentration of phenol in
the cavity wall after application of phenol, two biopsies
were curetted. Test 2 shows the concentrations in biopsy
A and B. Starting with 85% of liquefied phenol, the mean
initial local concentration of phenol measured was 557
Figure 2 Box Plot of concentration phenol and surface of bone cavity. Relation between concentrations of phenol measured in ethanol
(ppm) and surface of the bone cavity. No correlation is seen between the concentrations of phenol in ethanol in large or small cavities.
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ments have a large variation.
Patient 13 suffered from a small chondrosarcoma of the
metacarpal bone. The volume of the tumour was 4,4 cm
3.
Biopsy A and B show 25 and 17 ppm phenol respectively.
Nevertheless, the first sample in test 1 has a very high con-
centration of phenol in ethanol, 20974 ppm. The possible
explanation of these controversial measurements is, that
the location where the biopsy A and B were taken from
the metacarpal bone can almost only be cortical border of
the tumour. As cortical bone won’t absorb phenol very
well, the concentrations in biopsy A and B are low.
To investigate the effect of ethanol to dilute the appli-
cated phenol, 10 samples in 16 patients were collected. In
test 1, in all 16 cases the highest concentration of phenol
was measured in the first sample. However, the absolute
v a l u e sd i f f e r .D e s p i t et h ef a c tt h a tt h es a m ep r o c e d u r e
was performed in all cases, no procedure is the same
given the different volumes of the tumours varying from
4t o4 8c m
3. In patient number seven, the III
rd sample
shows an increase of the concentration phenol. From the
IV
th sample, the line decrease further on sample II. The
III
rd sample must be considered t ob eas a m p l ee r r o r .I n
these tests, the cavity was filled with ethanol ten times,
and phenol concentrations were measured. After washing
the cavity 6 times, in 10 of 16 patients the fraction of the
initial concentration of phenol is < 10%. The quantative
concentration of phenol is < 1300 ppm in all cases, which
means an estimated concentration of phenol of < 0,2%.
The degree of dilution is not influenced by the size of
the cavity after curettage. However, it is remarkable that
the highest concentrations in the first samples of test 1
all concerned small tumour volumes. This can be
explained by the relatively small volume of ethanol
where the phenol is diluted in.
We did not specifically study systemic effects of phe-
nol exposure in our patients; however, on retrospective
review, no adverse effects or secondary malignancies
were noted.
In the few studies that described measurements of
phenol, this was done by taking samples of urine, as
liquefied phenol is eliminated by the kidneys. However,
it is hard to define a ‘thresh hold’ for the toxic level.
This study shows that the adverse effects on the whole
body due to the use of liquefied phenol as adjuvant in
the intralesional curettage of benign and low-grade
malignant bone tumours are reduced to safe concentra-
tions by washing phenol out by ethanol. Phenol is a safe
adjuvant when used in a proper way, taking the above
mentioned statements into account. Washing the cavity
six times with ethanol 96% will be sufficient to diminish
the local concentration of liquefied phenol to an accep-
table concentration of < 0.2%.
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